Cisiv secures investment from Abbey International Finance and Ryan Group Holdings to expand its platform.
Abbey International Finance and Ryan Group Holdings have backed Cisiv to scale its operations and enhance its Baseline Plus software.
Cisiv is a technology company specialising in real-world late phase data collection for the life sciences sector. Its software platform provides efficient solutions for gathering prospective observational and primary data.
Cisiv has secured a joint investment from Abbey International Finance and Ryan Group Holdings. The capital will be deployed to accelerate the expansion of the company's Baseline Plus platform and scale its operations and commercial teams.
Developed for post-approval research, Baseline Plus supports non-interventional studies, rare disease registries, and health economics research. The technology has been utilised across more than 300 studies in over 60 countries, serving major pharmaceutical and biotechnology organisations globally.
Chief executive Dominic Farmer noted that the funding reflects a wider market shift towards efficient technology solutions for evidence generation. The latest injection aims to broaden the reach of the platform to additional life science partners.
From the founder
"We have seen a transformation of the market and a recognition that technology solutions can help deliver evidence more efficiently. We are thrilled to see the uptake of Baseline Plus to enable market access, real-world evidence for health outcomes and patient reported outcomes. This new funding will help us to scale our operations and commercial teams to help deliver real-world data to more life science partners."
Dominic Farmer
CEO and co-founder at Cisiv
Use of funds
- 01Continue product development
- 02Scale operations
- 03Invest in sales and marketing
